HAND DELIVERED APRIL 26, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Application No.: 09/225,502 Group Art Unit: 1644

Filed: January 6, 1999 Examiner: DeCloux, A.

Title: **Human FK506 Binding Proteins** Attny. Docket No. PF392

Amendment Fee Transmittal

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be **$ 1,290.00**.

The claim amendment fee has been estimated as shown below:

(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTITY	
Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Add. Fee	or	Rate	Add. Fee
Total	83	Minus	20	= 63	X9	$ **		X18	$ 1,134.00
Indep	6	Minus	4	= 2	X39	$ **		X78	$ 156.00
					Total	$ **	or	Total	**$ 1,290.00**

Please charge the required fee, and any other fee deemed necessary, to Deposit Account No. 08-3425. A duplicate of this sheet is enclosed.

Respectfully submitted

Dated: April 26, 2000

Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
(301) 309-8504 (telephone)

HAND DELIVERED APRIL 26, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Moore et al.

Application No.: 09/225,502 Group Art Unit: 1644

Filed: January 6, 1999 Examiner: DeCloux, A.

Title: **Human FK506 Binding Proteins** Attny. Docket No. PF392

REPLY UNDER 37 C.F.R. § 1.111
WITH STATEMENTS UNDER 37 C.F.R. § 1.825(a) AND (b)

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

In response to the Official Action mailed 27 October, 1999, please consider the following amendments and remarks. Submitted concurrently herewith is: (a) Petition for Extension of Time for a period of three (3) months, up to and including 27 April, 2000, accompanied by the appropriate fee; (b) and Amendment Fee Transmittal in duplicate; (c) a paper copy of a Substitute Sequence Listing; (d) a computer diskette containing the Substitute Sequence Listing in computer readable form; and (e) a Supplemental Information Disclosure Statement with revised Form PTO /SB/08, with copies of cited documents.

AMENDMENTS

In the Sequence Listing:

Please delete the original Sequence Listing, and replace it with the Substitute Sequence Listing submitted herewith.

In the Specification:

At page 14, between lines 14 and 15, insert the following text:

--Further polypeptides of the present invention include polypeptides which have at least 90% similarity, more preferably at least 95% similarity, and still more preferably at least 96%, 97%, 98% or 99% similarity to those described above. The polypeptides of the invention also comprise those which are at least 80% identical, more preferably at least 90% or 95% identical, still more preferably at least 96%, 97%, 98% or 99% identical to a polypeptide encoded by a deposited cDNA or to the polypeptide of SEQ ID NO:Y, and also include portions of such polypeptides with at least 30 amino acids and more preferably at least 50 amino acids.

By "% similarity" for two polypeptides is intended a similarity score produced by comparing the amino acid sequences of the two polypeptides using the Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group,